Search research articles
Contact Us
Filters
Showing results (71-80 of 91) with videos related to
Page
of 10
Sort By:
Clinical Lung Cancer
|
September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study
Pierre Mordant, Solenn Brosseau, Bernard Milleron, et al.
The Lancet. Oncology
|
February 21, 2012
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
JTO Clinical and Research Reports
|
August 14, 2025
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC
Jay M Lee, Jean-Louis Pujol, Jun Zhang, et al.
Molecular Cancer Therapeutics
|
March 14, 2012
High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway
Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Oncotarget
|
December 24, 2016
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial
Guénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2013
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
Virginie Westeel, Elisabeth Quoix, Marc Puyraveau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 27, 2015
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer
Jean-Louis Pujol, Johan F Vansteenkiste, Tommaso Martino De Pas, et al.
JCI Insight
|
August 8, 2020
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Camille Travert, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 91) with videos related to
Sort By:
Page
of 10
Clinical Lung Cancer
|
September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study
Pierre Mordant, Solenn Brosseau, Bernard Milleron, et al.
The Lancet. Oncology
|
February 21, 2012
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
JTO Clinical and Research Reports
|
August 14, 2025
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC
Jay M Lee, Jean-Louis Pujol, Jun Zhang, et al.
Molecular Cancer Therapeutics
|
March 14, 2012
High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway
Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Oncotarget
|
December 24, 2016
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial
Guénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2013
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
Virginie Westeel, Elisabeth Quoix, Marc Puyraveau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 27, 2015
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer
Jean-Louis Pujol, Johan F Vansteenkiste, Tommaso Martino De Pas, et al.
JCI Insight
|
August 8, 2020
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Camille Travert, et al.
Page
of 10